Previous Article | Next Article 
Infection and Immunity, April 2001, p. 2198-2210, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2198-2210.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Comparison of the exoS Gene and Protein
Expression in Soil and Clinical Isolates of Pseudomonas
aeruginosa
Michael W.
Ferguson,1,*
Jill A.
Maxwell,1,
Timothy S.
Vincent,2
Jack
da
Silva,3 and
Joan C.
Olson2
Biology Department, Coastal Carolina
University, Conway, South Carolina 29528-60541;
Department of Pathology and Laboratory Medicine, Medical
University of South Carolina, Charleston, South Carolina
294252; and Department of Biology,
East Carolina University, Greenville, North Carolina
278583
Received 2 August 2000/Returned for modification 6 October
2000/Accepted 28 December 2000
 |
ABSTRACT |
Exoenzyme S (ExoS) is translocated into eukaryotic cells by the
type III secretory process and has been hypothesized to function in
conjunction with other virulence factors in the pathogenesis of
Pseudomonas aeruginosa. To gain further understanding of
how ExoS might contribute to P. aeruginosa survival and
virulence, ExoS expression and the structural gene sequence were
determined in P. aeruginosa soil isolates and compared with
ExoS of clinical isolates. Significantly higher levels of ExoS
ADP-ribosyltransferase (ADPRT) activity were detected in culture
supernatants of soil isolates compared to those of clinical isolates.
The higher levels of ADPRT activity of soil isolates reflected both the
increased production of ExoS and the production of ExoS having a higher specific activity. ExoS structural gene sequence
comparisons found the gene to be highly conserved among soil and
clinical isolates, with the greatest number of nonsynonymous
substitutions occurring within the region of ExoS encoding GAP
function. The lack of amino acid changes in the ADPRT region in
association with a higher specific activity implies that other factors
produced by P. aeruginosa or residues outside the ADPRT
region are affecting ExoS ADPRT activity. The data are consistent with
ExoS being integral to P. aeruginosa survival in the soil
and suggest that, in the transition of P. aeruginosa from
the soil to certain clinical settings, the loss of ExoS expression is favored.
 |
INTRODUCTION |
Pseudomonas aeruginosa is
an opportunistic pathogen that can produce severe infections or death
when the person affected has a compromised immune system or severe
tissue damage (2). While P. aeruginosa can
readily adapt to growth within a human host if allowed access, its
primary residence is within the environment, where it can be found in a
number of habitats, including soil, water, plant and animal surfaces,
and decaying organic matter (3, 31, 53, 55, 63). Although
the precise ecological niche of P. aeruginosa is unknown, it
likely functions, along with other pseudomonads, in decomposition and
environmental recycling within the soil (21, 55, 57).
Factors that contribute to the virulence of P. aeruginosa in
the human host, such as adhesins, invasins, and resistance to
desiccation, are the same as those that contribute to its adaptability
in the environment.
Exoenzyme S (ExoS) has been implicated as a virulence factor of
P. aeruginosa; however, its precise role in the
pathogenicity of this organism remains unknown. ExoS is directly
translocated into eukaryotic cells by the contact-dependent type III
secretory process (61) and, as such, it provides the
bacterium with a mechanism for manipulating the eukaryotic cells it
encounters. In support of ExoS contributing to P. aeruginosa
pathogenicity, bacterial translocation of ExoS into epithelial cells
results in a general inactivation of cellular function, as recognized by the inhibition of DNA synthesis, loss of focal adhesion, cell rounding, and microvillus effacement (46). ExoS cellular
toxicity has also been found to parallel the opportunistic nature of
P. aeruginosa infections, with compromised epithelial cell
monolayers being more sensitive to the effects of bacterially
translocated ExoS than healthy confluent, polarized monolayers
(12, 40). While the mechanism of action of ExoS leading to
altered cell function is only partially understood, the evidence
supports the view that both its amino-terminal
GTPase-activating (GAP) activity (19) and
carboxy-terminal ADP-ribosyltransferase (ADPRT) activity (30) contribute to these effects (17, 19, 39,
59). Notably, the ADPRT activity of ExoS has a strict
requirement for a eukaryotic protein cofactor, 14-3-3 proteins
(7), emphasizing a functional link between this activity
and eukaryotic cells. The ability of ExoS to inactivate eukaryotic cell
function, combined with its preferential toxicity for compromised
epithelial cells, is consistent with ExoS providing the bacterium with
a means of selectively targeting and interfering with the function of
eukaryotic cells it encounters.
While an extensive number of studies have been performed to determine
the contribution of ExoS to P. aeruginosa virulence in
clinical settings, the role of ExoS in the survival of P. aeruginosa in the environment remains relatively unexplored. Our
studies have focused on examining the role of ExoS in the fitness of
P. aeruginosa in its natural environmental habitat, with the
notion that this might provide insight into the function of ExoS in the P. aeruginosa infectious process. To assess the relevance of
ExoS production to P. aeruginosa survival in the
environment, we analyzed P. aeruginosa soil isolates for the
production of ExoS and then compared both ExoS production and the
exoS gene sequence of soil and clinical isolates. We
detected the exoS gene in all soil isolates examined, a
finding which is consistent with the exoS gene being more
prevalent in P. aeruginosa within the soil than previously reported for clinical isolates (11). While the
exoS gene sequence of soil and clinical isolates was found
to be highly conserved, the ExoS ADPRT activity was significantly
higher in culture supernatants of soil isolates compared to clinical
isolates. The data support the idea that ExoS production is favored in
P. aeruginosa soil isolates and, as such, may be more
integral to P. aeruginosa survival in soil than in certain
clinical habitats.
 |
MATERIALS AND METHODS |
Soil collection and P. aeruginosa isolation.
Eight of the soil isolates examined in this study were obtained using a
standard soil probe from soil samples taken from random locations
throughout Horry and Georgetown Counties in South Carolina. Isolates
were obtained by laying out 6-m transects across each location, and
five samples that were 15-cm deep were taken at 1-m intervals across
the transect. The samples were bulked in zip-lock bags and held on ice
until processing. Following collection, the soil samples were processed
as outlined by Green et al. (21). Fifty grams of each soil
sample was placed in a flask containing 100 ml of sterile distilled
water. The contents were shaken for 1 h at 300 rpm in a water bath
at room temperature. A 0.5-ml aliquot of the soil solution was added to
a capped tube with 4.5 ml of sterile salts plus acetamide (SA) broth (5 g of NaCl, 0.2 g of MgSO4, 1 g of
NH4H2PO4, 1 g of
K2HPO4, and 20 g of acetamide [Sigma Chemical Co., St. Louis, Mo.] per 1 liter of distilled
H2O) (22, 54) and incubated without shaking at
42°C for 24 to 48 h. A 0.1-ml aliquot of this culture was spread
on plates of King's B plus cetrimide (hexadecyltrimethylammonium
bromide; Sigma) (KBC) medium (4, 29) and incubated for 24 to 48 h at 42°C. Bacterial colonies that were fluorescent on KBC
plates were streaked on plates of King's A medium (29) to
check for pyocyanin production. Isolates that produced both fluorescein
and pyocyanin, grew at 42°C, and had an odor characteristic of
P. aeruginosa were subsequently verified as P. aeruginosa based on biochemical characteristics by the Clinical
Microbiology Laboratory at the Medical University of South Carolina,
Charleston. Two additional P. aeruginosa soil isolates, U1
and U3, were isolated from a creosote-contaminated site in Fairhope,
Ala., and were provided by Pamela Morris.
Bacterial strains and growth conditions.
The following
clinical P. aeruginosa isolates were used in this study:
strain 388, a burn wound isolate (1), and its derivatives 388
S and 388
T (33, 60) were provided by Dara Frank;
PA01, a wound isolate (24); DG1, a cystic fibrosis (CF)
lung isolate (5); PA103, a sputum isolate
(38); FRD1 (45), its derivative, FRD2
(20), DO62, and DO249 are CF isolates provided by Dennis Ohman; strain ATCC 27853 is a blood isolate obtained from the American
Type Culture Collection (ATCC); strain WR5 (49) was provided by Barbara lglewski; and PAK (ATCC 25102) is included among
the clinical isolates, although its origin is uncertain. Soil isolates
examined in this study include CCU1 to CCU6, CCU8, CCU9, U1, and U3.
Stock cultures of all strains were maintained in 10% sterile skim milk
at
70°C. For short-term laboratory maintenance, cultures were
maintained on Luria-Bertani (LB) agar plates and stored at 4°C. To
induce ExoS production in vitro, bacteria were cultured for 18 h
at 37°C in a chelated dialysate of Trypticase soy broth supplemented
with 10 mM nitrilotriacetic acid (Sigma), 1% glycerol, and 100 mM
monosodium glutamate (TSBD-N) medium (27, 34). The optical
density at 590 nm (OD590) of cultures was determined at
18 h to compare the growth rates of the bacterial strains.
Measurement of ExoS enzyme activity.
ExoS ADPRT activity was
assayed and distinguished from that of exotoxin A (ETA) using a defined
assay system which measured the incorporation of radiolabeled
ADP-ribose into the artificial substrate soybean trypsin inhibitor
(SBTI; Sigma) as previously described (34). In these
analyses, each 40-µl reaction mixture contained 0.2 M sodium acetate
(pH 6.0), 1 µM nicotinamide [U-14C]adenine dinucleotide
(252 Ci/mol; Amersham Life Sciences, Arlington Heights, Ill.), 100 µM
SBTI, a 40 nM concentration of the 14-3-3
, co-factor (Upstate
Biotechnology, Inc., Lake Placid, N.Y.), and 10 µl of culture
supernatant, diluted as indicated. The reaction mixtures were incubated
at 25°C for 30 or 40 min and stopped by the addition of 40 µl of
ice-cold 20% trichloroacetic acid (TCA). The mixture was then spotted
on 0.45-µm-pore-size HA filters (Millipore, Bedford, Mass.) on a
vacuum manifold, washed twice with 5% TCA and once with ethanol, and
dried. The incorporation of radiolabel was determined by scintillation
counting and quantified as picomoles or femtomoles of ADP-ribose
transferred per minute to SBTI per supernatant volume. The ExoS ADPRT
activity of each isolate was calculated relative to the slope of the
dilution curve within the linear range of the ADPRT assay. To relate
ExoS ADPRT activity to total protein secretion, protein concentrations
in culture supernatants were determined based on densitometry analysis
of 10 µl of culture supernatant resolved on sodium dodecyl sulfate (SDS)-10% polyacrylamide gel electrophoresis (PAGE) gels and stained with Coomassie blue. This method of analysis both allowed a
visualization of culture supernatant proteins and circumvented high
background protein levels associated with bacterial medium. The
specific activity of ExoS of each isolate was calculated as the ratio
of ExoS ADPRT activity to ExoS protein concentrations in culture supernatants, the latter being determined based on immunoblot analyses
(described below). Statistical analyses of quantified ExoS activity
levels were performed using SigmaStat Statistical Software version
2.0 and the indicated test.
Immunoblot analysis of ExoS in culture supernatants and cell
extracts.
Culture supernatants of P. aeruginosa growth
in ExoS induction media were resolved on SDS-7.5% PAGE gels using the
method of Laemmli (36). Immunoblots were performed
according to the method of Towbin et al. (58) by
transferring the resolved culture supernatants to polyvinylidene
difluoride membranes (Millipore) and probing them with antisera,
produced using previously described methods (47), against
either native ExoS or ExoS reduced and denatured with 5%
-mercaptoethanol and 8 M urea, respectively, gel purified from
strain DG1. Immunoblots were developed using a peroxidase-conjugated
goat anti-rat immunoglobulin G (IgG; Sigma) and visualized by enhanced
chemiluminescence (ECL; Amersham). Quantification of ExoS was performed
on immunoblot images within the linear concentration range, and
densitometry values were obtained using the NIH image version 1.6 program and related to a previously quantified ExoS standard.
Genomic DNA purification and amplification of the
exoS structural gene.
DNA was purified from overnight
Luria broth cultures of P. aeruginosa strains using the
salting-out procedure (41) of the PureGene DNA isolation
kit (Gentra Systems, Inc., Minneapolis, Minn.) according to
manufacturer's specifications for purifying DNA from gram-negative
bacteria. Two sets of PCR primers, synthesized at the DNA synthesis
facility at the Medical University of South Carolina, were used to
isolate the exoS gene from P. aeruginosa genomic
DNA. Primer set 1 consisted of the following: (upper) 5'-GTCAGCATATGCATATTCAATCGCT-3',
which included an NdeI restriction site (underlined),
with the ATG start site of ExoS indicated in boldface, and (lower)
5'-CGAACCGAATTCTCAGGCCAGATCA-3', which included an EcoRI site (underlined), with the
TGA stop codon of ExoS in boldface. Primer Set 2 consisted of: (upper)
5'-GTCAGCATATGCATATTCAATCGCTTCAGCAG-3', which extended beyond the upper primer of set 1, and (lower)
5'-GCATGGATCCGCTGCCGAGCCAAGAATC-3', which is
downstream of the exoS structural gene of strain 388 and
includes a BamHI site (underlined). PCRs were performed
using a GeneAmp PCR System 9700 machine (PE Applied Biosystems, Foster City, Calif.). Each 50-µl reaction mixture contained 29.5 µl of distilled water, 10 µl of a 5× buffer solution containing 1.7 mM
MgCl2 (Gibco-BRL, Gaithersburg, Md.), 1 µl of each primer
(25 µM), 1 µl of each deoxynucleoside triphosphate (10 µM;
Gibco-BRL), 2.5 µl of dimethyl sulfoxide (Sigma), 1 µl of genomic
DNA (100 ng/ml), and 1 µl of Elongase Enzyme Mix (Gibco-BRL). The
Elongase Mix contains Taq polymerase and the proofreading
Pyrococcus sp. strain GB-D polymerase and was used to reduce
the possibility of sequence errors in the PCR amplification of ExoS.
The polymerase Elongase was added after 5 min at 98°C as a "hot
start." The PCR temperature cycles differed for the two primer sets.
The cycle for primer set 1 was as follows: 98°C (5 min); 80°C (2 min); 20 cycles of 94°C (30 s), 60°C (30 s, ramped down 0.5°C
lower each cycle, to an endpoint of 50°C), and 68°C (90 s); and
then 20 cycles of 94°C (30 s), 50°C (30 s), and 68°C (90 s). The
cycle for primer set 2 was as follows: 98°(5 min); 80°(2 min); 16 cycles of 94°C (30 s), 68°C (30 s ramped downed down 0.5°C lower
every cycle, to an endpoint of 60°C), and 68°C (90 s); and then 24 cycles of 94°C (30 s), 60°C (30 s), and 68°C (90 s).
Preparation of exoS PCR products for sequencing.
exoS PCR products were purified by excising the appropriate
sized band from 1% agarose gels, following electrophoresis using TAE
buffer (40 mM Tris-acetate, 1 mM EDTA; pH 8.0) for approximately 30 min
at 100 V. The DNA was extracted from the agarose gel slices using a
GeneClean kit, a silica-based DNA purification procedure (Bio 101, Vista, Calif.), according to the manufacturer's specifications. The
exoS PCR products were sequenced directly without cloning at
the DNA sequencing facility at the Medical University of South Carolina
using an ABI 377 automated DNA sequencer.
Sequence comparison.
Computer manipulations of sequence data
were performed using the BLAST programs available at the National
Center for Biotechnology Information website
(http://www.ncbi.nlm.nih.gov) and, for multiple sequence alignments,
CLUSTALW 1.8, available at Baylor College of Medicine's Search
Launcher Web Site (http://searchlauncher.bcm.tmc.edu/searchlauncher). Nucleotide sequences were aligned using the PileUp program of the
Wisconsin Package of sequence analysis programs (GCG version 10;
Madison, Wis.). The mean number of synonymous nucleotide substitutions per potential synonymous site (dS), the mean
number of nonsynonymous substitutions per potential nonsynonymous site
(dN), and their variances were estimated from
all pairwise comparisons of the sequences being analyzed by using
established methods (42, 43). These nucleotide distances
(proportion of nucleotide differences) were used to determine the form
of natural selection operating at the protein level, where
dS > dN indicates
purifying selection (selection against amino acid changes) and
dN > dS indicates
positive selection (selection for amino acid changes)
(25). The null hypothesis of no difference between
dS and dN was tested
using a two-tailed Z test (44). Evolutionary trees were
constructed using the neighbor-joining method (52). When
nucleotide distances between sequences corrected for multiple
substitutions at a site (28) were
0.05, as for
exoS sequences, the neighbor-joining method was applied to
the distances. When nucleotide distances were much greater, such that
dS was greater than 0.5, indicating the
saturation of synonymous sites, as in the case of distances between the
ExoT sequence and the ExoS sequences, the neighbor-joining method was
applied to amino acid distances (proportion of amino acid differences)
between sequences (44). The level of confidence in
internal branches of a tree (those separating clusters of sequences) was determined by running 1,000 bootstrap pseudoreplicates
(44). Branch lengths of the ExoS tree in terms of the
number of synonymous nucleotide substitutions per potential synonymous
site (bS) and the number of nonsynonymous
substitutions per potential nonsynonymous site
(bN) were estimated from proportional synonymous
(pS) and nonsynonymous
(pN) distances between pairs of sequences
(42) using Rzhetsky and Nei's (51) method of
computing branch lengths (64).
 |
RESULTS |
Soil survey.
A survey for the presence of P. aeruginosa in soils was conducted as part of an undergraduate
research project (23). Approximately 16% of soils
surveyed were positive for P. aeruginosa. These soils were
predominantly sandy and acidic in nature, but individual soils were
variable with respect to both percent sand fraction and pH. Nine
isolates from this survey were obtained for further study and labeled
CCU1 to CCU9. Culture CCU7 was lost early in the process and does not
appear in these studies. The phenotypic characteristics of these soil
isolates when grown under identical conditions were consistent with
each isolate being different. Two other P. aeruginosa
strains, U1 and U3, isolated from a different geographical region, were
introduced into the study at a later time to evaluate whether the
findings on ExoS production extended to a more distant geographical location.
Analyses of ExoS production by environmental isolates.
Preliminary assays of soil isolates, CCU1 to CCU9, grown under ExoS
induction conditions, found all but one strain, CCU1, to produce ExoS
ADPRT activity in culture supernatants (Fig.
1). Further examination of the
supernatants by immunoblot analyses using antibodies produced either
against the native or the reduced-denatured form of ExoS detected
variation in the amount of ExoS produced by the individual soil
isolates (Fig. 2A). Variation was also detected in the levels of ExoS of the clinical strains, which were
produced and analyzed in parallel for comparison. The antiserum produced against the native form of ExoS cross-reacted with the highly
homologous protein ExoT (60), while that produced against the reduced-denatured form of ExoS favored specific reactivity with
ExoS. The differential intensities of the ExoS banding patterns of the
two antisera are consistent with their recognition of different epitopes on ExoS. Immunoblot analyses of cell extracts of the soil
isolates found relative levels of ExoS to closely correspond to those
observed in culture supernatants (Fig. 2B). This indicates that
differences in ExoS production by these isolates occurred at the level
of gene expression rather than secretion.

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 1.
ExoS ADPRT activity in culture supernatants of soil
isolates. The eight CCU soil isolates, indicated by the respective
designations C1 to C6, C8, and C9, were cultured under ExoS induction
conditions for 18 h, and 10 µl of culture supernatant was
assayed for ExoS ADPRT activity. The results are expressed as the
femtomoles of ADP-ribose transferred per minute. The mean and standard
error (SE) of assays performed in duplicate from cultures grown and
analyzed in parallel in three independent studies are represented.
|
|

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoblot analyses of ExoS produced by soil and
clinical isolates. (A) Equal volumes (4 µl) of culture supernatants
from soil and clinical isolates grown in parallel under ExoS induction
conditions were resolved by SDS-PAGE on 7.5% polyacrylamide gels and
immunoblotted with antisera produced against the native (upper blot) or
the reduced-denatured form of ExoS (lower blot). (B) Cell extracts (4 µl of a twofold concentrate) were resolved as described above and
immunoblotted with antisera produced against the native form of ExoS.
ExoS proteins were detected using peroxidase-conjugated goat anti-rat
IgG and ECL. The blots are representative of one of three independent
studies performed. Std represents an ExoS or ExoT standard, previously
quantified to have 20 ng of ExoS. Supernatants from CCU isolates are
labeled C1 to C6, C8, and C9, and the clinical isolates are PAO1 (lane
01), 388 (lane 88), and DG1 (DG).
|
|
Quantification of ExoS ADPRT activity in culture supernatants of
soil and clinical isolates.
To further compare the properties of
ExoS produced among soil and clinical isolates, ExoS ADPRT activity was
quantified in culture supernatants of the strains grown, processed, and
assayed for ADPRT enzymatic activity in parallel, under identical
conditions (Fig. 3A and B). As shown in
Fig. 3A, differences were observed in the levels of ExoS ADPRT activity
among the soil isolates when serial dilutions of culture supernatants
were assayed for activity. The highest levels of ExoS ADPRT activity
were detected in culture supernatants of strains CCU2 and CCU6, with
the lowest levels of activity produced by strains CCU4, CCU8, and CCU1.
ExoS ADPRT activity of each isolate was quantified relative to the
slope of the dilution curve within the linear range of the assay (see Fig. 4 and 5). The results from these studies are consistent with immunoblot analyses in supporting that differences exist in the amount
of ExoS being produced by soil isolates.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Quantification of ExoS ADPRT activity in culture
supernatants of soil and clinical isolates. Serial dilutions of culture
supernatants from the indicated soil isolates (A) and clinical isolates
(B) were assayed for ADPRT activity, and the mean values of analyses
performed in parallel in two independent studies are represented. (C)
ExoS ADPRT activities of soil isolates from a different geographical
site and of additional clinical isolates were compared in a second
independent study in cultures grown and assayed for ADPRT activity in
parallel. Strain CCU2 was included in these studies as an internal
culture control, and ADPRT results were normalized to those of panels A
and B using an internal ADPRT assay control. The results are expressed
as femtomoles of ADP-ribose transferred per minute, and values obtained
in the linear range of the assay were used to quantify ExoS ADPRT of
the individual isolates. Soil isolates are strains CCU1 to CCU6, CCU8,
and CCU9 (C1 to C6, C8, and C9), U1, and U3. Clinical isolates are
strains 388 (curve 88), DG1 (DG), PAO1 (O1), FRD1 (F1), FRD2 (F2),
PA103 (103) 388 T ( T), 388 S ( S), DO62 (curve 62), DO249
(curve 249), WR5 (WR), and PAK.
|
|
More notable in comparisons of Fig.
3A and B were the general lower
levels of ExoS production detected in culture supernatants
of clinical
isolates than in soil isolates. Strain DG1 showed
the highest level of
ExoS ADPRT activity among these clinical
isolates, most closely
approaching that of the soil isolates.
Lower levels of ExoS ADPRT
activity were detected in supernatants
of strain 388, the prototype
ExoS-producing strain and its 388

T (non-ExoT-producing) derivative
strain (
60), the FRD1 and
FRD2 related strains, and still
lower levels were detected in
strain PA01 supernatants, the latter
previously recognized as
a low-ExoS-producing strain (
14).
Baseline levels of ExoS ADPRT
activity (~2 fmol min
1
ml
1) were detected in culture supernatants of strain
PA103, which
produces high levels of the ADP-ribosylating toxin ETA but
lacks
the
exoS structural gene (
11), confirming
the specificity of
the ExoS ADPRT assay for ExoS. Similarly, baseline
levels of ExoS
ADPRT activity (~0.4 fmol min
1
ml
1) were detected in supernatants of strain 388

S, a
derivative
of strain 388 that lacks the
exoS structural gene
(
33).
To examine whether the differences detected in ExoS production by soil
isolates and clinical isolates would be evident in
soil isolates from a
more distant geographical region and in other
clinical isolates, a
second study was performed in which two additional
soil isolates, U1
and U3, and the clinical isolates WR5, DO62,
DO249, and PAK were
cultured and assayed in parallel for ExoS
production (Fig.
3C). Soil
isolate CCU2 was cultured and assayed
in these studies as an internal
culture control, and ADPRT results
were normalized to those of previous
studies using an internal
ADPRT assay control. Again, these analyses
found the soil isolates
to produce higher levels of ExoS ADPRT than the
clinical isolates,
with strains WR5 and DO62 producing baseline levels
of ExoS ADPRT
activity. Statistical analyses of ExoS ADPRT activity in
culture
supernatants of the 10 soil and 9 clinical isolates shown in
Fig.
3 found the soil isolates to produce significantly higher levels
of ADPRT activity than the clinical isolates (
P = 0.002), based
on Student
t test analysis, with the mean
production levels of
ExoS ADPRT activity of soil and clinical
isolates being 209.1
± 36.9 and 48.9 ± 24.8 fmol
min
1 µl
1,
respectively.
Comparison of ExoS production with other bacterial culture
characteristics.
To evaluate how bacterial growth rates and levels
of protein secretion contributed to differences in ExoS production by
soil and clinical isolates, bacterial culture densities and culture supernatant protein concentrations were compared with the ExoS ADPRT
activity of the isolates. Representative comparisons of these
parameters in high- and low-ExoS-producing soil and clinical isolates
are shown in Fig. 4. Calculations of ExoS
ADPRT activity relative to protein levels in culture supernatants were
found to parallel the rates of ExoS production in general, with the exception of strain 388. Only low levels of protein were secreted by
strain 388, making the ratio of ExoS ADPRT activity to total supernatant protein high. No correlations were detected between bacterial growth rates or levels of secreted proteins and the production of ExoS in these analyses (r = 0.386 to
0.690) based on linear regression analyses. The data support the idea
that ExoS production is regulated independently of bacterial growth rate or levels of protein secretion when bacteria are grown in ExoS
induction medium.

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of ExoS production with bacterial culture
characteristics. Culture supernatant protein concentrations and
bacterial growth rates were compared with ExoS protein and ExoS ADPRT
activity of representative high- and low-ExoS-producing soil and
clinical isolates. Secreted proteins in culture supernatants were
compared and quantified based on an analysis of 10 µl of culture
resolved by SDS-10% PAGE gels and stained with Coomassie blue.
Bacterial growth rates were related to the OD590 of
cultures after growth in TSBD-N medium for 18 h. ExoS protein
concentrations were determined based on densitometry analysis of ExoS
immunoblots of culture supernatants, performed as described in the
legend to Fig. 2, and probed with antisera against both the native and
reduced-denatured forms of ExoS. ExoS ADPRT activity was quantified as
described in the legend to Fig. 3. The relative ratio of ExoS ADPRT
activity to the concentration of total secreted protein for each
isolate is indicated. Strains are labeled as in Fig. 3, and the
approximate mobilities of ExoT and ExoS are indicated by arrows.
|
|
To assess whether functional differences might exist in ExoS secreted
by the different strains, the relative specific activity
of ExoS in
culture supernatants of soil and clinical isolates
was calculated. The
specific activity of ExoS was quantified as
the ratio of ExoS ADPRT
activity relative to the concentration
of ExoS immunoreactive protein,
using densitometry analyses of
immunoblots probed with antisera to both
the native and denatured
forms of ExoS. Both antisera were used in ExoS
quantification
to help alleviate bias in detection due to antibody
specificity.
As shown in Fig.
5, the
calculated specific activity of ExoS produced
by the soil isolates was,
in general, higher than that of clinical
isolates, indicating that ExoS
produced by soil isolates was functionally
more active. The exceptions
to this were CCU1, which lacked detectable
ExoS production, and ExoS
produced by CCU4, which had a lower
specific activity, one closer to
that of the clinical isolates.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 5.
Specific ADPRT activity of ExoS produced by soil and
clinical isolates. The specific activity of ExoS in culture
supernatants of soil and clinical isolates was calculated based on the
ratio of quantified levels of ExoS ADPRT activity to ExoS protein
concentrations, determined by immunoblot analyses, and related to an
ExoS standard. The specific activity is expressed as femtomoles of
ADP-ribose transferred per minute per nanogram of ExoS protein in the
culture supernatants. The results represent the mean and SE of two
independent studies. Soil and clinical isolates are labeled as in Fig.
3.
|
|
Amplification of the exoS structural gene from soil
isolates.
Differences observed in the immunoreactivity and
specific activity of ExoS produced among soil and clinical isolates
suggested that variation might exist in the exoS structural
gene sequence of P. aeruginosa within these two habitats.
The exoS genes of two P. aeruginosa clinical
isolates, strains 388 and PAO1, have previously been determined and
were found to differ by only one amino acid residue, the former having
a valine and the latter having a methionine at residue 62 (15,
35). A valine residue was, however, detected at position 62 in
the exoS gene in the PAO1 genome sequence (56)
(GenBank accession number AE004801). Since the degree of conservation
of the exoS structural gene sequence between clinical and
environmental P. aeruginosa isolates has not been previously
examined, the complete nucleotide sequence of exoS from soil
isolates and additional clinical isolates was determined from the
respective PCR products.
Initial PCRs using primer set 1 allowed amplification of the
appropriate sized product from some but not all of the CCU soil
isolates (Fig.
6A). Primer set 2 amplified ExoS from all isolates
(Fig.
6B). The two primer sets
differed in that primer set 1 included
shorter regions of
hybridization, which defined the beginning
and end of the
exoS gene and resulted in the amplification of
a second
product. PCR products generated from primer set 2 were
used to
determine the
exoS gene sequences of soil and clinical
isolates examined this study.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 6.
Amplification of exoS structural genes from
P. aeruginosa soil and clinical isolates. The
exoS gene was amplified from the genomic DNA of the
indicated bacterial strains using primer set 1 (A) or primer set 2 (B)
(see Materials and Methods). Products were resolved on 1% agarose
gels. "L" indicates the DNA ladder, the CCU soil isolates are
numbered 1 to 6, 8, and 9, as indicated, and clinical strains 388 (lane
88) and DG1 (DG) are labeled.
|
|
Comparison of nucleotide sequences of soil and clinical
isolates.
The nucleotide sequences of the exoS genes
determined from PCR products were compared, along with the
exoS gene sequence of strain PAO1 (15) (GenBank
accession number X99471) to that of the prototype exoS gene
of strain 388 (35) (GenBank accession number L27629).
Analyses of the exoS genes of soil isolates found that CCU1,
which did not produce a detectable ExoS product based on ADPRT activity
or immunoblot analyses, maintained an exoS structural gene
identical to that of strain 388, as did clinical isolate ATCC 27853. The exoS genes of CCU6 and CCU9 were also found to be
identical to each other. The exoS genes of CCU2, CCU6, CCU9,
CCU8, and DG1 had only synonymous (silent) nucleotide substitutions when compared to exoS of strain 388 (Table
1), while those of CCU3, CCU4, CCU5, U1,
U3, FRD1, and PAK had both synonymous and nonsynonymous substitutions
(Table 1). The nonsynonymous nucleotide substitutions resulted in one
to six amino acid changes in ExoS, depending on the isolate (Table 1).
Nucleotide changes were further classified into transitions
(purine-to-purine or pyrimidine-to-pyrimidine shifts) and transversions
(purine-to-pyrimidine or pyrimidine-to-purine shifts) (42,
43), with transitions being typically more common than
transversions. Table 2 summarizes the
ExoS sequence data of all strains, with respect to strain 388 ExoS.
Sixty-one percent of nucleotide substitutions were synonymous
transitions in the third position, while 24% were synonymous
transversions in the third position. Fifteen percent of the
substitutions were nonsynonymous, with transitions occurring at
frequencies of 4 and 2% in the first and second positions,
respectively, and transversions occurring at frequencies of 3, 4, and
2% in the first, second, and third positions, respectively. Of
interest in the comparison of the ExoS sequences is the clustering of
synonymous substitutions in the region corresponding to residues 52 to
83 and the clustering of nonsynonymous substitutions in the region
corresponding to residues 157 to 191. Notable in the sequence
comparisons among soil and clinical isolates was the lack of
nonsynonymous substitutions in the region of ExoS predicted to form the
ADPRT active site cleft, thereby providing no direct explanation
for the increased specific activity detected in ExoS produced by soil
isolates. What was noticed instead was the clustering of amino acid
substitutions in the region involved in GAP function.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Synonymous and nonsynonymous substitutions in the
exoS gene of P. aeruginosa environmental and
clinical isolates compared to strain 388a
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Type of nucleotide substitution for exoS genes
of P. aeruginosa environmental and clinical isolates
compared to exoS gene of strain 388a
|
|
The evolution of the
exoS genes of clinical and
environmental isolates examined in this study was analyzed and is
displayed
as a tree showing three major clades (Fig.
7). Statistical comparisons
(two tailed)
of the number of synonymous substitutions per synonymous
site
(
dS) and the number of nonsynonymous
substitutions per nonsynonymous
site (
dN) were
performed to determine whether the
exoS gene was
under
positive selection, favoring amino acid replacement
(
dN >
dS), or under
purifying selection, favoring amino acid stability
(
dS >
dN). ExoS was
analyzed in this manner relative to (i) the
entire
exoS
gene, encoding amino acid residues 1 to 453; (ii)
the N-terminal
domain, residues 1 to 234; (iii) the C-terminal
domain, residues 235 to
453; (iv) the type III signal sequence
within residues 1 to 9 (
61); (v) the aggregation region, residues
1 to 99, predicted to interact with the chaperone, Orf1 (
13,
30);
(vi) the GAP homology region, defined by residues 107 to
191; and (vii)
the ADPRT active site cleft, defined by residues
316 to 403. When all
ExoS sequences were compared,
dS was
significantly
greater than
dN for the entire
exoS gene (
P < 0.001), its N-terminal
and
C-terminal domains (
P < 0.01), and within the
N-terminal domain,
the aggregation region (
P < 0.05),
indicating a strong purifying
selection for ExoS generally and these
regions specifically (Table
3). Similar
results were obtained when ExoS sequences of the
environmental and
clinical isolates were compared (not shown).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 7.
Evolutionary relationship of exoS nucleotide
sequences. The exoS tree was constructed using the
neighbor-joining method (52) on Jukes-Cantor corrected
nucleotide distances (28). The numbers on the tree are the
percentages of 1,000 bootstrap pseudo-replicates supporting internal
branches.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Mean dS and
dN per 100 sites as estimated from comparisons
between ExoS sequences, between CCU4 plus PAK and other ExoS
sequences, and between ExoT and ExoS sequences
|
|
When the most divergent
exoS genes, those of CCU4 and PAK,
were compared with all the other
exoS genes,
dS was again significantly
greater than
dN for the entire
exoS gene
(
P < 0.01), a finding
indicative of purifying
selection (Table
3). However, within
the GAP region of ExoS of CCU4 and
PAK, which includes the nonsynonymous
substitutions at residues 157, 159, and 162 in ExoS of CCU4,
dN was greater
than
dS, albeit not statistically significantly
so
(
P > 0.05). To further test the hypothesis of
positive selection
of the GAP domain in the evolution of CCU4 and PAK,
the method
of Zhang et al. (
64) was used to estimate the
rates of synonymous
(
bS) and nonsynonymous
(
bN) substitutions along the branches of
the
ExoS tree leading to CCU4 and PAK. This analysis showed a
significant
positive selection of GAP (
P < 0.05) along the branch
leading to CCU4 (
bN = 0.1616 ± 0.00910;
bS = 0.0 ± 0.0) using
a
one-tailed Z test with infinite degrees of freedom. The same
analyses
detected no positive selection of GAP along any other
branch, and there
was no positive selection of either the aggregation
domain or the ADPRT
domain along any branch in the ExoS tree.
While positive selection
indicates that a protein sequence is
still under selection pressure to
change, it does not indicate
the direction of change (i.e., indicating
gain or loss of a particular
function). The data support the notion
that while the ADPRT domain
is genetically stable, changes in the GAP
region are being favored
under certain conditions. This in turn
suggests that the evolution
of the ADPRT domain preceded the GAP region
and that the GAP domain
provides an additional adaptive advantage to
P. aeruginosa.
A third analysis was performed comparing the ExoT amino acid sequence
of strain 388 (
60) (GenBank accession number
L46800),
which is highly homologous to ExoS, with all ExoS sequences, to
gain
further understanding of the evolutionary relationship between
these
two proteins. The comparison revealed strong purifying selection
(
dS >
dN) for ExoT
and functional regions within ExoT (Table
3).
A tree constructed based
on the ExoT protein sequence and all
ExoS protein sequences shows the
distant divergence of ExoT from
ExoS, relative to the variation
observed in ExoS sequences (Fig.
8). The
tree also shows strong support (83% of the bootstrap samples)
for the
cluster of all ExoS proteins, excluding CCU4 and PAK,
suggesting an
early divergence of the latter among ExoS proteins.
The purifying
selection of ExoT and ExoS is further depicted in
Fig.
8 (inset), which
shows the distribution of nonsynonymous
substitutions throughout ExoT
and ExoS relative to strain 388
ExoS. The data support that during the
evolutionary divergence
of ExoS and ExoT, both proteins, and their
respective functional
regions, have undergone purifying selection. This
does not exclude
the possibility of positive selection associated with,
or occurring
shortly after, the divergence of these proteins.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 8.
Evolutionary relationship of ExoS and ExoT protein
sequences. The ExoS-ExoT tree was constructed using all ExoS protein
sequences and the strain 388 ExoT sequence (60) as
described in the legend to Fig. 7, except that the neighbor-joining
method was applied to amino acid distances between sequences. (Inset)
Nonsynonymous substitutions within ExoT and ExoS. The positions of
nonsynonymous substitutions within ExoS and ExoT, relative to ExoS of
strain 388, are indicated by vertical lines within the linear map of
the respective proteins, with the width of each line reflecting the
number of substituted amino acids. Predicted functional regions within
ExoS and ExoT are labeled and shaded. Numbers that define the amino
acid boundaries of the type III signal sequence (S) and aggregation
domain have been previously reported (61). The GAP and
ADPRT regions are defined based on homology with other GAP or ADPRT
proteins. The positions of residues integral to GAP function (R146 or
R149 in ExoS and ExoT, respectively) (19, 32) and ADPRT
activity in ExoS (E381) (37) and the homologous residue in
ExoT (E385) are marked by arrows.
|
|
 |
DISCUSSION |
The ubiquitous distribution of P. aeruginosa in nature
and clinical settings indicates a close link between the environmental organism and the opportunistic pathogen. ExoS is one of multiple factors believed to contribute to the virulence of P. aeruginosa as an opportunistic pathogen. While it has been
previously recognized that both environmental and clinical isolates
produce ExoS (26), the genetic and functional relationship
of ExoS produced in these two habitats has not been explored. The
purpose of our studies was to examine ExoS produced by soil isolates
and, through comparisons with clinical isolates, to gain an
understanding of the conservation of the ExoS structural gene, as well
as insight into the role of ExoS in P. aeruginosa virulence
and survival.
In a cursory survey of the soils in Horry and Georgetown counties in
South Carolina, P. aeruginosa was isolated from 16% of the
samples, indicating that it is relatively common in soils in this
region. Examination of ExoS production by these isolates found seven of
eight strains to produce high levels of ExoS ADPRT activity. Variations
were, however, detected in levels of ExoS cross-reactive protein among
the isolates when culture supernatants were examined by immunoblot
analyses. These variations were later confirmed in ADPRT activity
assays when serial dilutions of culture supernatants were assayed for
enzymatic activity and concentrations of ExoS ADPRT activity were
determined within the linear range of the dilution curve. Of interest
in comparisons of ExoS production of P. aeruginosa soil and
clinical isolates were the overall higher levels of ExoS ADPRT activity
produced by soil isolates. This difference was apparent in our initial
comparison of eight soil and five clinical isolates and then in a
second study comparing two soil isolates from a more distant
geographical location and four additional clinical isolates.
Statistical analysis of ExoS ADPRT activity of 10 soil and 9 clinical
isolates found production by soil isolates to be significantly greater
than that of clinical isolates (P = 0.002). When ExoS
production was related to bacterial growth rates or levels of protein
secretion, no significant correlations were detected, supporting the
idea that ExoS production was regulated independently of these culture characteristics.
To gain further understanding of the structure-function relationship of
ExoS produced by the different P. aeruginosa strains, the
specific activity of ExoS in culture supernatants (ADPRT activity per
nanogram of ExoS protein) was calculated for individual isolates. Considerable variation was detected in ExoS specific activity among the
isolates, with soil isolates in general producing ExoS with a higher
ADPRT activity than clinical isolates. When the exoS genes
of soil and clinical strains were sequenced to gain further
understanding of the molecular mechanism for the higher activity, no
obvious explanation based on amino acid substitutions was evident. This
points to the possibility that other factors produced by P. aeruginosa and/or amino acid substitutions outside the
ADPRT domain may be modulating ExoS ADPRT activity.
There is precedence for the notion that ExoS function or ADPRT activity
may be enhanced by either bacterial or eukaryotic factors. A chaperone,
Orf1, coordinately regulated with ExoS production, facilitates the
transport of ExoS from the prokaryotic cell and hence increases
secreted ExoS activity (15, 62). Within the eukaryotic
cell, the modulating effect of the 14-3-3 protein cofactor is required
for maximal ADPRT activity (7, 16). The potential therefore remains for these and/or other unidentified factors to act as
inhibitors or potentiators of the ExoS ADPRT activity and contribute to
the differences observed in activity in environmental and clinical
isolates. In this regard, we found that ExoS produced by soil isolates,
like clinical isolates, requires the 14-3-3 cofactor for ADPRT
activity, indicating that if an enhancing factor is produced by soil
isolates, it cannot replace the activity of the 14-3-3 cofactor.
Another factor that may influence ExoS activity in soil isolates is the
highly homologous and coordinately regulated protein ExoT. ExoT was
detected in all of the soil isolates examined in this study, based
either on immunoblot analyses or on PCR amplification of the ExoT
structural gene (unpublished observation). ExoS exists in a
high-molecular-weight complex with ExoT in culture supernatants (34) and, while there has been speculation as to the
potential competitive or coordinated function of these two proteins,
the specific effect of ExoT on ExoS function remains unknown.
Notably, relative to the possibility that residues outside the ADPRT
domain might be able to modulate ADPRT activity is the clustering of
amino acid substitutions in the GAP region of ExoS, sometimes in
association with a decrease in ADPRT activity. While relatively few
amino acid substitutions were detected in ExoS produced by soil and
clinical isolates, 7 of the 15 substitutions resulting in amino acid
changes occurred within the GAP homology region of ExoS. CCU4, which
had a lower level of ExoS ADPRT activity than the other soil isolates,
had the greatest number of amino acid substitutions, three of which
were within the GAP region (Ala-157 to Ser, Ser-159 to Asn, and Glu-162
to Lys). The ExoS of FRD1, CCU3, U1, and U3 also had amino acid
substitutions within the GAP region (Ser-121 to Asn, Arg-170 to Cys,
and Ala-191 to Ser, respectively). While it remains to be proven
whether the GAP region of ExoS is contributing to the differences in
ADPRT activity detected among the isolates, the increased amino
acid variation within this region identifies it as a candidate site for
modulation of ExoS function.
Analysis of the sequence variability of the exoS genes of 10 soil and 5 clinical P. aeruginosa isolates, a group which
includes the two previously sequenced exoS genes of strains
388 and PAO1, provided insight into the evolutionary relationship of
ExoS produced in these two settings. The inter-relatedness of the ExoS
proteins of the soil and clinical isolates is evident in the
interspersing of the exoS genes among the clades in the tree
shown in Fig. 7. While foci of silent or synonymous substitutions were
detected in soil isolates relative to strain 388, nucleotide
substitutions at these sites in many instances were identical to those
found in the other clinical isolates. The positioning of isolates
producing either low or high levels of ExoS ADPRT activity on the same
branch further highlights the lack of relationship between the
exoS gene sequence and the levels of ExoS production. The
data as a whole are consistent with the ExoS of clinical isolates
representing a fairly accurate cross section of that produced in
environmental settings. Comparisons of the variability of the ExoS
protein sequences to the ExoT sequence also provided insight into the
relatively distant divergence of these two proteins. The evidence of
strong purifying selection for both ExoS and ExoT in these analyses, and their respective functional domains, supports the idea that both
proteins maintain a stable, independent function within P. aeruginosa.
The increased rate of ExoS production and the prevalence of the
exoS structural gene in soil isolates imply the importance of ExoS to survival of P. aeruginosa in the soil. These
results are consistent with early studies of ExoS that found a high
percentage of environmental isolates (91%) to produce ExoS
(26). Conversely, the decreased rate of ExoS production by
clinical isolates, as well as the reported absence of the
exoS structural gene from cytotoxic corneal isolates
(11) or the lack of ExoS secretion from CF isolates
(9), indicates the possible lesser importance of ExoS in
certain clinical settlings. The production of ExoS by clinical
isolates, however, appears somewhat related to the site of infection,
as is evident from the general higher levels of ExoS production in
P. aeruginosa isolated from wound and urinary tract
infections (50). When ExoS expression is examined relative to that of other type III effector proteins, a preferred pattern of
expression emerges among P. aeruginosa strains. For
example, the paired expression of ExoU-ExoT or ExoS-ExoT has been noted in P. aeruginosa clinical isolates in the absence of the
paired expression of ExoU-ExoS or the expression of ExoS, ExoT, and
ExoU (10). Although ExoU production was not examined in
our studies, ExoS and ExoT expression or genes were detected in all
soil isolates, favoring the paired expression of ExoS and ExoT in the
soil. No conclusion can be drawn from our studies, however, as to the
relative efficiency of ExoS and ExoT production by soil isolates, due
to the method of detection of ExoT and the bias of the antisera used in
immunoblot analyses for ExoS. All data obtained from these analyses,
though, are consistent with ExoS production being favored and
upregulated in association with P. aeruginosa growth in the soil.
Based on the high expression of ExoS in the soil and assuming that the
soil is the point of origin for P. aeruginosa, it can be
hypothesized that the evolution of ExoS occurred as a result of a
selection pressure within this environment. The requirement for a
eukaryotic cofactor for ExoS ADPRT activity presumes that ExoS
coevolved with eukaryotic organisms. P. aeruginosa likely encounters a myriad of eukaryotic species in the soil, including plant
roots, free-living nematodes, protozoa, and fungi. Possible relationships that might introduce selection pressures in this environment are parasitic or commensal relationships on plant roots,
prey-predator relationships with protozoa and nematodes, and
competition for substrates with fungi. As P. aeruginosa
adapts to certain clinical settings, the selection pressure for ExoS production appears to be lessened, as indicated by decreased levels of
ExoS production or the lack of the structural gene, rather than
alterations in the gene sequence. While we can currently only speculate
as to the different advantages ExoS might offer P. aeruginosa in its interaction with eukaryotes in the soil versus clinical environments, the cellular sensitivities to ExoS notably mimic
the opportunistic lifestyle of P. aeruginosa. For example, relative to epithelial monolayers, confluent, polarized monolayers are
resistant to the effects of ExoS-producing P. aeruginosa, whereas compromised or subconfluent monolayers are sensitive (12, 40). In addition, when ExoS is translocated into sensitive
epithelial or fibroblastic cell lines, a general inactivation of cell
function is recognized, rather than an immediate cytotoxic effect
(40, 48). Similarly, the type III-mediated translocation
of ExoS into macrophages has been reported to have little effect on
viability (6) but can inhibit bacterial uptake
(15). Consistent with the role of ExoS as an anti-invasive
factor, both ExoS and ExoT have recently been found to interfere with
the uptake of P. aeruginosa by epithelial cells and
macrophages in an ADPRT-independent manner (8, 18). In
contrast to the above cell types, the promyeloblastic HL-60 cell line
appears to be resistant to the effects of ExoS (E. A. Rucks,
T. S. Vincent, J. C. Olson, Abstr. 100th Gen. Meet. Am. Soc.
Microbiol. 2000, abstr. B-329, p. 116, 2000). Based on these findings,
ExoS may provide an advantage to P. aeruginosa survival in
the soil through its ADPRT-dependent inactivation of eukaryotes it
encounters and its ADPRT-independent interference with bacterial
uptake. Alternatively in clinical settings, while the inactivation of
host cell function and antiphagocytic properties of ExoS might be
predicted to aid in the infectious process, the limited toxicity of
ExoS, combined with its inefficient targeting of cells of lymphoid
origin, may favor the production of more cytotoxic factors, such as
ExoU and ETA, at certain sites of P. aeruginosa infection.
Where ExoS is likely to come into play in the infectious process,
however, is when P. aeruginosa encounters damaged epithelial tissue.
We conclude from these studies that ExoS is integral to the survival of
P. aeruginosa in the soil but is less so in some clinical settings. In relating this finding to an understanding of the origin
and evolution of ExoS as a virulence factor, our data suggest that ExoS
existed prior to the evolutionary transition from the soil organism to
the human pathogen. This, in turn, supports the view that the lower
frequency of expression of ExoS in certain clinical settings relates to
the loss of the gene or gene expression rather than to its limited acquisition.
 |
ACKNOWLEDGMENTS |
We thank Dara Frank and Joseph Barbieri for their advice and
helpful discussions during these studies and Dennis Ohman, Dara Frank,
Barbara Iglewski, and Pamela Morris for providing us with P. aeruginosa strains. We also appreciate the contribution of Kathy
Dolan, Jennifer O'Brien, Eileen McGuffie, and Zachery Olson to these studies.
This work was supported by Public Health Service grants AI41180
(M.W.F.) and AI41694 (J.C.O.) from the National Institute of Allergy
and Infectious Diseases.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Biology
Department, Coastal Carolina University, P.O. Box 261954, Conway, SC
29528-6054. Phone: (843) 349-2214. Fax: (843) 349-2201. E-mail:
ferguson{at}coastal.edu.
Present address: Department of Microbiology and Immunology, East
Carolina University School of Medicine, Greenville, NC 27858.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Bjorn, M. J.,
O. R. Pavlovskis,
M. R. Thompson, and B. H. Iglewski.
1979.
Production of exoenzyme S during Pseudomonas aeruginosa infections of burned mice.
Infect. Immun.
24:837-842[Abstract/Free Full Text].
|
| 2.
|
Bodey, G. P.,
R. Bolivar,
V. Fainstein, and L. Jadeja.
1993.
Infections caused by Pseudomonas aeruginosa.
Rev. Infect. Dis.
5:270-313.
|
| 3.
|
Botzenhart, K., and G. Doring.
1993.
Ecology and epidemiology of Pseudomonas aeruginosa, p. 1-18.
In
M. Campa, M. Bendinelli, and H. Friedman (ed.), Pseudomonas aeruginosa as an opportunistic pathogen. Plenum Press, New York, N.Y.
|
| 4.
|
Brown, V. I., and E. J. L. Lowbury.
1965.
Use of an improved centrimide agar medium and other culture methods for Pseudomonas aeruginosa.
J. Clin. Pathol.
18:752-756[Abstract/Free Full Text].
|
| 5.
|
Cash, H. A.,
D. E. Woods,
B. McCullough,
W. G. Johanson, Jr., and J. A. Bass.
1979.
A rat model of chronic respiratory infection with Pseudomonas aeruginosa.
Am. Rev. Respir. Dis.
119:453-459[Medline].
|
| 6.
|
Coburn, J., and D. W. Frank.
1999.
Macrophages and epithelial cells respond differently to the Pseudomonas aeruginosa type III secretion system.
Infect. Immun.
67:3151-3154[Abstract/Free Full Text].
|
| 7.
|
Coburn, J.,
A. V. Kane,
L. Feig, and D. M. Gill.
1991.
Pseudomonas aeruginosa exoenzyme S requires a eukaryotic protein for ADP-ribosyltransferase activity.
J. Biol. Chem.
266:6438-6446[Abstract/Free Full Text].
|
| 8.
|
Cowell, B. A.,
D. Y. Chen,
D. W. Frank,
A. J. Vallis, and S. M. Fleiszig.
2000.
ExoT of cytotoxic Pseudomonas aeruginosa prevents uptake by corneal epithelial cells.
Infect. Immun.
68:403-406[Abstract/Free Full Text].
|
| 9.
|
Dacheux, D.,
B. Toussiant,
M. Richard,
G. Brochier,
J. Croize, and I. Attree.
2000.
Pseudomonas aeruginosa cystic fibrosis isolates induce rapid type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.
Infect. Immun.
68:2916-2924[Abstract/Free Full Text].
|
| 10.
|
Finck-Barbancon, V.,
J. Goranson,
L. Zhu,
T. Sawa,
J. P. Wiener-Kronish,
S. M. Fleiszig,
C. Wu,
L. Mende-Mueller, and D. W. Frank.
1997.
ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.
Mol. Microbiol.
25:547-557[CrossRef][Medline].
|
| 11.
|
Fleiszig, S. M.,
J. P. Wiener-Kronish,
H. Miyazaki,
V. Vallas,
K. E. Mostov,
D. Kanada,
T. Sawa,
T. S. Yen, and D. W. Frank.
1997.
Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S.
Infect. Immun.
65:579-586[Abstract].
|
| 12.
|
Fleiszig, S. M.,
D. J. Evans,
N. Do,
S. Shin, and K. E. Mostov.
1997.
Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity.
Infect. Immun.
65:2861-2867[Abstract].
|
| 13.
|
Frank, D. W.
1997.
The exoenzyme S regulon of Pseudomonas aeruginosa.
Mol. Microbiol.
26:621-629[CrossRef][Medline].
|
| 14.
|
Frank, D. W.,
G. Nair, and H. P. Schweizer.
1994.
Construction and characterization of chromosomal insertional mutations of the Pseudomonas aeruginosa exoenzyme S trans-regulatory locus.
Infect. Immun.
62:554-563[Abstract/Free Full Text].
|
| 15.
|
Frithz-Lindsten, E.,
Y. Du,
R. Rosqvist, and A. Fosberg.
1997.
Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments.
Mol. Microbiol.
25:1125-1139[CrossRef][Medline].
|
| 16.
|
Fu, H.,
J. Coburn, and R. J. Collier.
1993.
The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family.
Proc. Natl. Acad. Sci. USA
90:2320-2324[Abstract/Free Full Text].
|
| 17.
|
Ganesan, A. K.,
T. S. Vincent,
J. C. Olson, and J. T. Barbieri.
1999.
Pseudomonas aeruginosa exoenzyme S disrupts Ras-mediated signal transduction by inhibiting guanine nucleotide exchange factor-catalyzed nucleotide exchange.
J. Biol. Chem.
274:21823-21829[Abstract/Free Full Text].
|
| 18.
|
Garrity-Ryan, L.,
B. Kazmierczak,
R. Koval,
J. Comolli,
A. Hauser, and J. N. Engel.
2000.
The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of Pseudomonas aeruginosa by epithelial cells and macrophages.
Infect. Immun.
68:7100-7113[Abstract/Free Full Text].
|
| 19.
|
Goehring, U. M.,
G. Schmidt,
K. J. Pederson,
K. Aktories, and J. T. Barbieri.
1999.
The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases.
J. Biol. Chem.
274:36369-36372[Abstract/Free Full Text].
|
| 20.
|
Goldberg, J. B., and D. E. Ohman.
1984.
Cloning and expression of a gene involved in the production of alginate.
J. Bacteriol.
158:1115-1121[Abstract/Free Full Text].
|
| 21.
|
Green, S. K.,
M. N. Schroth,
J. J. Cho,
S. D. Kominos, and V. V. Vitanza-Jack.
1974.
Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa.
Appl. Microbiol.
28:987-991[Medline].
|
| 22.
|
Hedberg, M.
1969.
Acetamide agar medium selective for Pseudomonas aeruginosa.
Appl. Microbiol.
17(3):481[Medline].
|
| 23.
|
Holden, C.,
T. Todd,
M. Ferguson,
J. C. Olson, and E. McGuffie.
1996.
Survey for the occurrence of exoenzyme S in non-clinical isolates of Pseudomonas aeruginosa.
Bull. South. Calif. Acad. Sci.
LVIII:103-104.
|
| 24.
|
Holloway, B. W., and A. F. Morgan.
1986.
Genome organization in Pseudomonas.
Annu. Rev. Microbiol.
40:79-105[CrossRef][Medline].
|
| 25.
|
Hughes, A. L.
1999.
Adaptive evolution of genes and genomes.
Oxford University Press, Oxford, England.
|
| 26.
|
Iglewski, B. H.
1988.
Pseudomonas toxins, p. 249-265.
In
M. C. Hardegree, and A. T. Tu (ed.), Handbook of toxins, vol. 4. Marcel Dekker, New York, N.Y.
|
| 27.
|
Iglewski, B. H., and D. Kabat.
1975.
NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa.
Prod. Natl. Acad. Sci. USA
72:2284-2288[Abstract/Free Full Text].
|
| 28.
|
Jukes, T. H., and C. R. Cantor.
1969.
Evolution of protein molecules, p. 21-132.
In
H. N. Munro (ed.), Mammalian protein metabolism. Academic Press, Inc., New York, N.Y.
|
| 29.
|
King, E. O.,
M. K. Ward, and D. E. Raney.
1954.
Two simple media for the demonstration of pyocyanin and fluorescein.
J. Lab. Clin. Med.
44:301-307[Medline].
|
| 30.
|
Knight, D. A.,
V. Finck-Barbancon,
S. M. Kulich, and J. T. Barbieri.
1995.
Functional domains of Pseudomonas aeruginosa exoenzyme S.
Infect. Immun.
63:3182-3186[Abstract].
|
| 31.
|
Kominos, S. D.,
C. E. Copeland,
B. Grosiak, and B. Postic.
1972.
Introduction of Pseudomonas aeruginosa into a hospital via vegetables.
Appl. Microbiol.
24:567-570[Medline].
|
| 32.
|
Krall, R.,
U. M. Goehring,
K. Aktories, and J. T. Barbieri.
2000.
Pseudomonas aeruginosa ExoT is a RhoGTP-ase activating protein.
Infect. Immun.
68:6066-6068[Abstract/Free Full Text].
|
| 33.
|
Kulich, S. M.,
D. W. Frank, and J. T. Barbieri.
1995.
Expression of recombinant exoenzyme S of Pseudomonas aeruginosa.
Infect. Immun.
63:1-8[Abstract].
|
| 34.
|
Kulich, S. M.,
D. W. Frank, and J. T. Barbieri.
1993.
Purification and characterization of exoenzyme S from Pseudomonas aeruginosa 388.
Infect. Immun.
61:307-313.
|
| 35.
|
Kulich, S. M.,
T. L. Yahr,
L. M. Mende-Mueller,
J. T. Barbieri, and D. W. Frank.
1994.
Cloning the structural gene for the 49-kDa form of exoenzyme S (ExoS) from Pseudomonas aeruginosa strain 388.
J. Biol. Chem.
269:10431-10437[Abstract/Free Full Text].
|
| 36.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 37.
|
Liu, S.,
S. M. Kulich, and J. T. Barbieri.
1996.
Identification of glutamic acid 381 as a candidate active site residue of Pseudomonas aeruginosa exoenzyme S.
Biochemistry
35:2754-2758[CrossRef][Medline].
|
| 38.
|
Lui, P. V.
1966.
The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. III. Identity of the lethal toxins produced in vitro and in vivo.
J. Infect. Dis.
116:481-489[Medline].
|
| 39.
|
McGuffie, E. M.,
D. W. Frank,
T. S. Vincent, and J. C. Olson.
1998.
Modification of Ras in eukaryotic cells by Pseudomonas aeruginosa exoenzyme S.
Infect. Immun.
66:2607-2613[Abstract/Free Full Text].
|
| 40.
|
McGuffie, E. M.,
J. E. Fraylick,
D. J. Hazen-Martin,
T. S. Vincent, and J. C. Olson.
1999.
Differential sensitivity of human epithelial cells to Pseudomonas aeruginosa exoenzyme S.
Infect. Immun.
67:3494-3503[Abstract/Free Full Text].
|
| 41.
|
Miller, S. A.,
D. D. Dykes, and H. F. Polesky.
1988.
A simple salting out procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res.
16:1215[Free Full Text].
|
| 42.
|
Nei, M., and T. Gojobori.
1986.
Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.
Mol. Biol. Evol.
3:418-426[Abstract].
|
| 43.
|
Nei, M., and L. Jin.
1989.
Variances of the average numbers of nucleotide substitutions within and between populations.
Mol. Biol. Evol.
6:418-426.
|
| 44.
|
Nei, M., and S. Kumar.
2000.
Molecular evolution and phylogenetics.
Oxford University Press, Oxford, England.
|
| 45.
|
Ohman, D. E., and A. M. Chakrabarty.
1981.
Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate.
Infect. Immun.
33:142-148[Abstract/Free Full Text].
|
| 46.
|
Olson, J. C.,
J. E. Fraylick,
E. M. McGuffie,
K. M. Dolan,
T. L. Yahr,
D. W. Frank, and T. S. Vincent.
1999.
Interruption of multiple cellular processes in HT-29 epithelial cells by Pseudomonas aeruginosa exoenzyme S.
Infect. Immun.
67:2847-2854[Abstract/Free Full Text].
|
| 47.
|
Olson, J. C.,
A. N. Hamood,
T. S. Vincent,
E. H. Beachey, and B. H. Iglewski.
1990.
Identification of functional epitopes of Pseudomonas aeruginosa exotoxin A using synthetic peptides and subclone products.
Mol. Immunol.
27:981-993[CrossRef][Medline].
|
| 48.
|
Olson, J. C.,
E. M. McGuffie, and D. W. Frank.
1997.
Effects of differential expression of the 49-kilodalton exoenzyme S by Pseudomonas aeruginosa on cultured eukaryotic cells.
Infect. Immun.
65:248-256[Abstract].
|
| 49.
|
Pavlovskis, O. R.,
B. H. Iglewski, and M. Pollack.
1978.
Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2.
Infect. Immun.
19:29-33[Abstract/Free Full Text].
|
| 50.
|
Rumbaugh, K. P.,
J. A. Griswold, and A. N. Hamood.
1999.
Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection: variations in virulence factors and virulence genes.
J. Hosp. Infect.
43:211-218[CrossRef][Medline].
|
| 51.
|
Rzhetsky, A., and M. Nei.
1993.
Theoretical foundation of the minimum-evolution method of phylogenetic inference.
Mol. Biol. Evol.
10:1073-1095[Abstract].
|
| 52.
|
Saitou, N., and M. Nei.
1987.
The neighbour-joining method: a new method for reconstructing phylogenetic trees.
Mol. Biol. Evol.
4:406-425[Abstract].
|
| 53.
|
Schroth, M. N.,
D. C. Hildebrand, and M. P. Starr.
1981.
Phytopathogenic members of the genus Pseudomonas, p. 701-718.
In
M. P. Starr, H. Stolp, H. G. Truper, A. Balows, and H. G. Schlegel (ed.), The prokaryotes: a handbook on habitats, isolation and identification of bacteria, vol. 1. Springer-Verlag, Berlin, Germany.
|
| 54.
|
Smith, R. F., and S. L. Dayton.
1972.
Use of acetamide broth in the isolation of Pseudomonas aeruginosa from rectal swabs.
Appl. Microbiol.
24:143-145[Medline].
|
| 55.
|
Stolp, H., and D. Gadkari.
1981.
Nonpathogenic members of the genus Pseudomonas, p. 719-741.
In
M. P. Starr, H. Stolp, H. G. Truper, A. Balows, and H. G. Schlegel (ed.), The prokaryotes: a handbook on habitats, isolation, and identification of bacteria, vol. 1. Spring-Verlag, Berlin, Germany.
|
| 56.
|
Stover, C. K.,
X. Q. Pham,
A. L. Erwin,
S. D. Mizoguchi,
P. Warrener,
M. J. Hickey,
F. S. L. Brinkman,
W. O. Hufnagle,
D. J. Kowalik,
M. Lagrou,
R. L. Garber,
L. Goltry,
E. Tolentino,
S. Westbrock-Wadman,
Y. Yaun,
L. L. Brody,
S. N. Coulter,
K. R. Folger,
A. Kas,
K. Larbig,
R. Lim,
K. Smith,
D. Spencer,
G. K.-S. Wong,
Z. Wu,
I. T. Paulsen,
J. Reizer,
M. H. Saier,
R. E. W. Hancock,
S. Lory, and M. V. Olson.
2000.
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.
Nature
406:959-964[CrossRef][Medline].
|
| 57.
|
Sylvia, D. M.,
J. J. Fuhrmann,
P. G. Hartel, and D. A. Zuberer.
1998.
Principles and applications of soil microbiology.
Prentice-Hall, Englewood Cliffs, N.J.
|
| 58.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 59.
|
Vincent, T. S.,
J. E. Fraylick,
E. M. McGuffie, and J. C. Olson.
1999.
ADP-ribosylation of oncogenic Ras proteins by Pseudomonas aeruginosa exoenzyme S in vivo.
Mol. Microbiol.
32:1054-1064[CrossRef][Medline].
|
| 60.
|
Yahr, T. L.,
J. T. Barbieri, and D. W. Frank.
1996.
Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa.
J. Bacteriol.
178:1412-1419[Abstract/Free Full Text].
|
| 61.
|
Yahr, T. L.,
J. Goranson, and D. W. Frank.
1996.
Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway.
Mol. Microbiol.
22:991-1003[CrossRef][Medline].
|
| 62.
|
Yahr, T. L.,
A. K. Hovey,
S. M. Kulich, and D. W. Frank.
1995.
Transcriptional analysis of the Pseudomonas aeruginosa exoenzyme S structural gene.
J. Bacteriol.
177:1169-1178[Abstract/Free Full Text].
|
| 63.
|
Zechman, J. M., and J. L. E. Casida.
1982.
Death of Pseudomonas aeruginosa in soil.
Can. J. Microbiol.
28:788-794[Medline].
|
| 64.
|
Zhang, J.,
H. F. Rosenberg, and M. Nei.
1998.
Positive Darwinian selection after gene duplication in primate ribonuclease genes.
Proc. Natl. Acad. Sci. USA
95:3708-3713[Abstract/Free Full Text].
|
Infection and Immunity, April 2001, p. 2198-2210, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2198-2210.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lin, H.-H., Huang, S.-p., Teng, H.-C., Ji, D.-D., Chen, Y.-S., Chen, Y.-L.
(2006). Presence of the exoU Gene of Pseudomonas aeruginosa Is Correlated with Cytotoxicity in MDCK Cells but Not with Colonization in BALB/c Mice. J. Clin. Microbiol.
44: 4596-4597
[Abstract]
[Full Text]
-
Rocha, C. L., Rucks, E. A., Vincent, D. M., Olson, J. C.
(2005). Examination of the Coordinate Effects of Pseudomonas aeruginosa ExoS on Rac1. Infect. Immun.
73: 5458-5467
[Abstract]
[Full Text]
-
Rucks, E. A., Olson, J. C.
(2005). Characterization of an ExoS Type III Translocation-Resistant Cell Line. Infect. Immun.
73: 638-643
[Abstract]
[Full Text]
-
Lanotte, P., Watt, S., Mereghetti, L., Dartiguelongue, N., Rastegar-Lari, A., Goudeau, A., Quentin, R.
(2004). Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J Med Microbiol
53: 73-81
[Abstract]
[Full Text]
-
Ajayi, T., Allmond, L. R., Sawa, T., Wiener-Kronish, J. P.
(2003). Single-Nucleotide-Polymorphism Mapping of the Pseudomonas aeruginosa Type III Secretion Toxins for Development of a Diagnostic Multiplex PCR System. J. Clin. Microbiol.
41: 3526-3531
[Abstract]
[Full Text]
-
Rucks, E. A., Fraylick, J. E., Brandt, L. M., Vincent, T. S., Olson, J. C.
(2003). Cell line differences in bacterially translocated ExoS ADP-ribosyltransferase substrate specificity. Microbiology
149: 319-331
[Abstract]
[Full Text]
-
Wilderman, P. J., Vasil, A. I., Martin, W. E., Murphy, R. C., Vasil, M. L.
(2002). Pseudomonas aeruginosa Synthesizes Phosphatidylcholine by Use of the Phosphatidylcholine Synthase Pathway. J. Bacteriol.
184: 4792-4799
[Abstract]
[Full Text]
-
Fraylick, J. E., La Rocque, J. R., Vincent, T. S., Olson, J. C.
(2001). Independent and Coordinate Effects of ADP-Ribosyltransferase and GTPase-Activating Activities of Exoenzyme S on HT-29 Epithelial Cell Function. Infect. Immun.
69: 5318-5328
[Abstract]
[Full Text]
-
Wilderman, P. J., Vasil, A. I., Johnson, Z., Wilson, M. J., Cunliffe, H. E., Lamont, I. L., Vasil, M. L.
(2001). Characterization of an Endoprotease (PrpL) Encoded by a PvdS-Regulated Gene in Pseudomonas aeruginosa. Infect. Immun.
69: 5385-5394
[Abstract]
[Full Text]